A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)

NCT06129539 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Central Precocious Puberty

Interventions

DRUG: Debio 4326

Sponsor

Debiopharm International SA